Microbix Biosystems Inc. (MBX.TO) Research

Microbix Biosystems Inc. is a life science enterprise dedicated to advancing human health globally, including markets across North America and Europe. Established in 1988 and headquartered in Mississauga, Canada, the company specializes in developing and marketing unique biological and technological products. A significant part of its business involves producing essential biological reagents for the diagnostic industry. This encompasses antigens vital for immunoassays, alongside its distinctive Quality Assessment and Proficiency (QAP) products. These QAPs are instrumental for clinical laboratories, providing support for proficiency testing, the development and validation of diagnostic assays, and optimizing routine lab operations. Furthermore, Microbix applies its deep biological knowledge and infrastructure to create additional proprietary offerings. Among these are DxTM, a viral transport medium crucial for stabilizing patient specimens prior to laboratory analysis, and Kinlytic Urokinase, a biopharmaceutical thrombolytic drug employed to treat blood clots. The company channels its QAP sales to accreditation organizations, diagnostic companies, and clinical laboratories via an extensive network of regional distributors.

Market snapshot

Symbol
MBX.TO
Price
$0.31
Day change
+1.67%
Market cap
$41.9M
P/E ratio
-7.44x
52-week range
0.21-0.34
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • DIAGNOS Inc. (ADK.V)
  • BriaCell Therapeutics Corp. (BCT.TO)
  • BioMark Diagnostics Inc. (BUX.CN)
  • Charlotte's Web Holdings, Inc. (CWEB.TO)
  • Rapid Dose Therapeutics Corp. (DOSE.CN)
  • Defence Therapeutics Inc. (DTC.CN)
  • Gemina Laboratories Ltd. (GLAB.CN)
  • MediPharm Labs Corp. (LABS.TO)

Open Microbix Biosystems Inc. (MBX.TO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.